Φορτώνει......
Immunotherapy for Glioblastoma: Current Progress and Challenges
Glioblastoma is a highly lethal brain cancer with a median survival rate of less than 15 months when treated with the current standard of care, which consists of surgery, radiotherapy and chemotherapy. With the recent success of immunotherapy in other aggressive cancers such as advanced melanoma and...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Front Immunol |
|---|---|
| Κύριοι συγγραφείς: | , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Frontiers Media S.A.
2021
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8158294/ https://ncbi.nlm.nih.gov/pubmed/34054867 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2021.676301 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|